A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies.

[1]  J. Klingström,et al.  Vaccination of C57/BL6 mice with Dobrava hantavirus nucleocapsid protein in Freund's adjuvant induced partial protection against challenge. , 2004, Vaccine.

[2]  D. Krüger,et al.  High yields of stable and highly pure nucleocapsid proteins of different hantaviruses can be generated in the yeast Saccharomyces cerevisiae. , 2004, Journal of biotechnology.

[3]  D. Krüger,et al.  Yeast-expressed hantavirus Dobrava nucleocapsid protein induces a strong, long-lasting, and highly cross-reactive immune response in mice. , 2004, Viral immunology.

[4]  D. Krüger,et al.  Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice. , 2004, Viral immunology.

[5]  A. Roseman,et al.  An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. , 2004, Virology.

[6]  D. Krüger,et al.  First Molecular Identification of Human Dobrava Virus Infection in Central Europe , 2004, Journal of Clinical Microbiology.

[7]  G. Pari,et al.  Generation of a Recombinant Cytomegalovirus for Expression of a Hantavirus Glycoprotein , 2003, Journal of Virology.

[8]  H. Netter,et al.  Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. , 2003, Vaccine.

[9]  Y Choi,et al.  Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. , 2003, Vaccine.

[10]  B. Hjelle,et al.  Genetic Interaction between Distinct Dobrava Hantavirus Subtypes in Apodemus agrarius and A. flavicollis in Nature , 2003, Journal of Virology.

[11]  C. Howard,et al.  Review of an Inactivated Vaccine against Hantaviruses , 2003, Intervirology.

[12]  B. Hjelle,et al.  Emerging Viruses: The Case ‘Hantavirus’ , 2003, Intervirology.

[13]  A. Plyusnin,et al.  Hantaviruses in Estonia , 2002, Journal of medical virology.

[14]  D. Krüger,et al.  Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. , 2002, Vaccine.

[15]  E. B. Butler,et al.  Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  B. Hjelle,et al.  Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus). , 2002, The Journal of general virology.

[17]  A. Plyusnin,et al.  Cross-Protection against Challenge with Puumala Virus after Immunization with Nucleocapsid Proteins from Different Hantaviruses , 2002, Journal of Virology.

[18]  J. Schiller,et al.  Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. , 2001, Virology.

[19]  D. Krüger,et al.  Hantavirus infections and their prevention. , 2001, Microbes and infection.

[20]  E. Thompson,et al.  DNA Vaccination with the Hantaan Virus M Gene Protects Hamsters against Three of Four HFRS Hantaviruses and Elicits a High-Titer Neutralizing Antibody Response in Rhesus Monkeys , 2001, Journal of Virology.

[21]  Y. Sohn,et al.  Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. , 2001, Yonsei medical journal.

[22]  D. Krüger,et al.  Clinical characterization of Dobrava hantavirus infections in Germany. , 2001, Clinical nephrology.

[23]  D. Krüger,et al.  Dobrava hantavirus causes hemorrhagic fever with renal syndrome in central Europe and is carried by two different Apodemus mice species , 2001 .

[24]  D. Krüger,et al.  Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. , 2000, Virology.

[25]  D. Krüger,et al.  Interaction of wild‐type and naturally occurring deleted variants of hepatitis B virus core polypeptides leads to formation of mosaic particles , 2000, FEBS letters.

[26]  C. Schmaljohn,et al.  Clinical evaluation of a vaccinia‐vectored Hantaan virus vaccine , 2000, Journal of medical virology.

[27]  D. Krüger,et al.  Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. , 1999, The American journal of tropical medicine and hygiene.

[28]  D. Krüger,et al.  New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. , 1999, Journal of biotechnology.

[29]  A. Leslie,et al.  The crystal structure of the human hepatitis B virus capsid. , 1999, Molecular cell.

[30]  Å. Lundkvist,et al.  Hemorrhagic fever with renal syndrome in the Dolenjska region of Slovenia--a 10-year survey. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  D. Krüger,et al.  HBV Core Particles Allow the Insertion and Surface Exposure of the Entire Potentially Protective Region of Puumala Hantavirus Nucleocapsid Protein , 1999, Biological chemistry.

[32]  A. Vaheri,et al.  Isolation and characterization of Dobrava hantavirus carried by the striped field mouse (Apodemus agrarius) in Estonia. , 1999, The Journal of general virology.

[33]  R. Zinkernagel,et al.  T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Ksiazek,et al.  Retrospective serological and genetic study of the distribution of hantaviruses in Greece , 1998, Journal of medical virology.

[35]  A. Vaheri,et al.  Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment , 1997, Journal of virology.

[36]  B. Böttcher,et al.  Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy , 1997, Nature.

[37]  C. Snapper,et al.  The immunoglobulin class switch: beyond "accessibility". , 1997, Immunity.

[38]  A. Vaheri,et al.  Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. , 1996, Virology.

[39]  Y. Chu,et al.  Genetic and antigenic properties of Dobrava virus: a unique member of the Hantavirus genus, family Bunyaviridae. , 1995, The Journal of general virology.

[40]  Y. Chu,et al.  A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus , 1995, Journal of virology.

[41]  C. Schmaljohn.  Prospects for vaccines to control viruses in the family Bunyaviridae , 1994 .

[42]  F. Schödel,et al.  Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination , 1994, Infection and immunity.

[43]  P. Pumpens,et al.  Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen , 1993, Journal of virology.

[44]  J. McCormick,et al.  Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. , 1992, The American journal of tropical medicine and hygiene.

[45]  A. Vaheri,et al.  Cloning and sequencing of Puumala virus Sotkamo strain S and M RNA segments: evidence for strain variation in hantaviruses and expression of the nucleocapsid protein. , 1992, The Journal of general virology.

[46]  H. Will,et al.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity , 1992, Journal of virology.

[47]  J. Poolman,et al.  Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines , 1991, Infection and immunity.

[48]  D. Bishop,et al.  Physicochemical analysis of the hepatitis B virus core antigen produced by a baculovirus expression vector. , 1990, The Journal of general virology.

[49]  M. Nassal,et al.  Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein , 1990, Journal of virology.

[50]  J. Dalrymple,et al.  Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants , 1990, Journal of virology.

[51]  R. Lanford,et al.  Expression of hepatitis B virus core and precore antigens in insect cells and characterization of a core-associated kinase activity. , 1990, Virology.

[52]  B. Clarke,et al.  Immunological properties of hepatitis B core antigen fusion proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Borisova,et al.  Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface , 1989, FEBS letters.

[54]  L. Zentilin,et al.  A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids , 1989, Journal of virology.

[55]  H. Schaller,et al.  Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus , 1989, Journal of virology.

[56]  A. Moriarty,et al.  Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. , 1987, Journal of immunology.

[57]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[58]  D. Milich,et al.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. , 1986, Science.

[59]  K. Matsubara,et al.  Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons , 1986, Journal of virology.

[60]  J. E. Richmond,et al.  Electron microscopy of hepatitis B core antigen synthesized in E. coli , 1982, Nature.

[61]  E. Puré,et al.  T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells , 1982, The Journal of experimental medicine.

[62]  Walter Gilbert,et al.  Hepatitis B virus genes and their expression in E. coli , 1979, Nature.

[63]  D. Krüger,et al.  Coding strategy of the S and M genomic segments of a hantavirus representing a new subtype of the Puumala serotype , 2005, Archives of Virology.

[64]  Jukka Mustonen,et al.  Hantavirus infections in Europe. , 2003, The Lancet. Infectious diseases.

[65]  J. Hooper,et al.  Vaccines against hantaviruses. , 2001, Current topics in microbiology and immunology.

[66]  Å. Lundkvist,et al.  T-helper and humoral responses to Puumala hantavirus nucleocapsid protein: identification of T-helper epitopes in a mouse model. , 2001, The Journal of general virology.

[67]  D. Krüger,et al.  Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. , 1998, Vaccine.

[68]  A. Lucas,et al.  Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. , 1993, Vaccine.

[69]  G. Borisova,et al.  [Genetically engineered mutants of the core antigen of the human hepatitis B virus preserving the ability for native self-assembly]. , 1988, Doklady Akademii nauk SSSR.

[70]  B. Clarke,et al.  Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein , 1987, Nature.

[71]  D. Montgomery,et al.  Unusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiae. , 1986, Gene.

[72]  A. Vaheri,et al.  Hemorrhagic fever with renal syndrome in Finland: ecology and virology of nephropathia epidemica. , 1982, Scandinavian journal of infectious diseases. Supplementum.

[73]  A. Sutton,et al.  Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines. , 1980, Progress in clinical and biological research.

[74]  K. Johnson,et al.  Isolation of the etiologic agent of Korean Hemorrhagic fever. , 1978, The Journal of infectious diseases.